The Outlook section from the MD&A provides a good update to the timeline. I have a feeling that we'll be hearing about raising funds for this work soon.

"We will continue to need to raise funds for future operations and for preclinical programs potentially leading to the filing of one or a number of investigational new drugs (INDs).

Within the xB3 program, management intends to advance preclinical development of the xB3-TZM program (001 in Brain Metastasis), key development milestones and current target dates for completion (calendar year) include: initiation of manufacturing (Q1 of 2018), request FDA Type B (pre-IND) meeting (Q3 of 2018), initiation of toxicology program (Q2 of 2019) and begin our first-in-man Ph 1 /2 clinical study (Q4 of 2019). The company also intends to fund further work on its other preclinical pipeline programs: the 002 program in Glioblastoma, the company plans to complete preclinical proof-of-concept (POC) (Q3 of 2018), initiate manufacturing (Q4 of 2018) and initiate toxicology studies (Q4 of 2019). For the 007 program in neurodegeneration, the company will plan to complete preclinical POC (Q4 of 2018) and initiate manufacturing (Q1 of 2019). Provided we are able to secure adequate funding, our intent is to expand the scope-of-work on these projects as discussed above with the intention of creating greater value for our intellectual property and on building stronger licensing partnerships."